{"entity": "researcher", "timestamp": "2026-08-21T02:35:10.544Z", "family": "V\u00e5gesj\u00f6", "given": "Evelina", "initials": "E", "orcid": "0000-0002-4254-6875", "affiliations": ["Ilya Pharma AB, Uppsala, Sweden.", "Division of Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/51776c4ea8ee4d75bab4606a906dc4de.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/51776c4ea8ee4d75bab4606a906dc4de"}}, "publications": [{"entity": "publication", "iuid": "85b052f8bc8840c9a219c9cc3b5909fb", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/85b052f8bc8840c9a219c9cc3b5909fb.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/85b052f8bc8840c9a219c9cc3b5909fb"}}, "title": "Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models.", "authors": [{"family": "\u00d6hnstedt", "given": "Emelie", "initials": "E", "orcid": "0009-0000-3545-8802", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/71ffd40be3da4d3baae5627b1467db82.json"}}, {"family": "Do\u00f1as", "given": "Cristian", "initials": "C"}, {"family": "Parv", "given": "Kristel", "initials": "K"}, {"family": "Pang", "given": "Yanhong", "initials": "Y"}, {"family": "Lofton Tomenius", "given": "Hava", "initials": "H"}, {"family": "Carrasco L\u00f3pez", "given": "Macarena", "initials": "M"}, {"family": "Gannavarapu", "given": "Venkata Ram", "initials": "VR"}, {"family": "Choi", "given": "Jacqueline", "initials": "J"}, {"family": "Ovezik", "given": "Maria", "initials": "M"}, {"family": "Frank", "given": "Peter", "initials": "P"}, {"family": "Jorvid", "given": "Margareth", "initials": "M"}, {"family": "Roos", "given": "Stefan", "initials": "S"}, {"family": "V\u00e5gesj\u00f6", "given": "Evelina", "initials": "E", "orcid": "0000-0002-4254-6875", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/51776c4ea8ee4d75bab4606a906dc4de.json"}}, {"family": "Phillipson", "given": "Mia", "initials": "M", "orcid": "0000-0002-2387-0266", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/265c9b3e11de4fcaa270a0eb20faf65c.json"}}], "type": "journal article", "published": "2024-08-01", "journal": {"title": "Am J Physiol Gastrointest Liver Physiol", "issn": "1522-1547", "volume": "327", "issue": "2", "pages": "G140-G153", "issn-l": null}, "abstract": "Treatments of colitis, inflammation of the intestine, rely on induction of immune suppression associated with systemic adverse events, including recurrent infections. This treatment strategy is specifically problematic in the increasing population of patients with cancer with immune checkpoint inhibitor (ICI)-induced colitis, as immune suppression also interferes with the ICI-treatment response. Thus, there is a need for local-acting treatments that reduce inflammation and enhance intestinal healing. Here, we investigated the effect and safety of bacterial delivery of short-lived immunomodulating chemokines to the inflamed intestine in mice with colitis. Colitis was induced by dextran sulfate sodium (DSS) alone or in combination with ICI (anti-PD1 and anti-CTLA-4), and Limosilactobacillus reuteri R2LC (L. reuteri R2LC) genetically modified to express the chemokine CXCL12-1\u03b1 (R2LC_CXCL12, emilimogene sigulactibac) was given perorally. In addition, the pharmacology and safety of the formulated drug candidate, ILP100-Oral, were evaluated in rabbits. Peroral CXCL12-producing L. reuteri R2LC significantly improved colitis symptoms already after 2 days in mice with overt DSS and ICI-induced colitis, which in benchmarking experiments was demonstrated to be superior to treatments with anti-TNF-\u03b1, anti-\u03b14\u03b27, and corticosteroids. The mechanism of action involved chemokine delivery to Peyer's patches (PPs), confirmed by local CXCR4 signaling, and increased numbers of colonic, regulatory immune cells expressing IL-10 and TGF-\u03b21. No systemic exposure or engraftment could be detected in mice, and product feasibility, pharmacology, and safety were confirmed in rabbits. In conclusion, peroral CXCL12-producing L. reuteri R2LC efficiently ameliorates colitis, enhances mucosal healing, and has a favorable safety profile.NEW & NOTEWORTHY Colitis symptoms are efficiently reduced by peroral administration of probiotic bacteria genetically modified to deliver CXCL12 locally to the inflamed intestine in several mouse models.", "doi": "10.1152/ajpgi.00022.2024", "pmid": "38780469", "labels": [], "xrefs": [], "notes": [], "created": "2026-08-20T12:03:05.552Z", "modified": "2026-08-20T12:03:05.725Z"}, {"entity": "publication", "iuid": "e188bd7d6eda492da33d45b91e6486af", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/e188bd7d6eda492da33d45b91e6486af.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/e188bd7d6eda492da33d45b91e6486af"}}, "title": "Accelerated Wound Healing in Minipigs by On-Site Production and Delivery of CXCL12 by Transformed Lactic Acid Bacteria.", "authors": [{"family": "\u00d6hnstedt", "given": "Emelie", "initials": "E"}, {"family": "Lofton Tomenius", "given": "Hava", "initials": "H"}, {"family": "Frank", "given": "Peter", "initials": "P"}, {"family": "Roos", "given": "Stefan", "initials": "S"}, {"family": "V\u00e5gesj\u00f6", "given": "Evelina", "initials": "E", "orcid": "0000-0002-4254-6875", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/51776c4ea8ee4d75bab4606a906dc4de.json"}}, {"family": "Phillipson", "given": "Mia", "initials": "M"}], "type": "journal article", "published": "2022-01-19", "journal": {"title": "Pharmaceutics", "issn": "1999-4923", "volume": "14", "issue": "2", "issn-l": null}, "abstract": "Non-healing wounds are a growing medical problem and result in considerable suffering. The lack of pharmaceutical treatment options reflects the multistep wound healing process, and the complexity of both translation and assessment of treatment efficacy. We previously demonstrated accelerated healing of full-thickness wounds in mice following topical application of the probiotic bacteria Limosilactobacillus reuteri R2LC transformed to express CXCL12. In this study, safety and biological effects of a freeze-dried formulation of CXCL12-producing L. reuteri (ILP100) were investigated in induced full-thickness wounds in minipigs, and different wound healing evaluation methods (macroscopic, planimetry, 2D-photographs, 3D-scanning, ultrasound) were compared. We found that treatment with ILP100 was safe and accelerated healing, as granulation tissue filled wound cavities 1 day faster in treated compared to untreated/placebo-treated wounds. Furthermore, evaluation using planimetry resulted in 1.5 days faster healing than using 2D photographs of the same wounds, whereas the areas measured using 2D photographs were smaller compared to those obtained from 3D scans accounting for surface curvatures, whereas ultrasound imaging enabled detailed detection of thin epithelial layers. In conclusion, topical administration of the drug candidate ILP100 warrants further clinical development as it was proven to be safe and to accelerate healing using different evaluation methods in minipigs.", "doi": "10.3390/pharmaceutics14020229", "pmid": "35213962", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC8876577"}, {"db": "pii", "key": "pharmaceutics14020229"}], "notes": [], "created": "2026-08-20T13:43:01.045Z", "modified": "2026-08-20T13:43:01.065Z"}]}